Category: AbbVie

AbbVie’s (ABBV) Epcoritamab Gets Approval in Europe for DLBCL – September 26, 2023

AbbVie (ABBV Quick QuoteABBV – Free Report) and partner Genmab (GMAB Quick QuoteGMAB – Free Report) announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). DLBCL is a common, aggressive and fast-growing form of non-Hodgkin’s lymphoma…

Continue Reading AbbVie’s (ABBV) Epcoritamab Gets Approval in Europe for DLBCL – September 26, 2023

The data in our DNA | Opinion

In the two decades since the Human Genome Project was declared finished (if not complete), DNA sequencing technology has advanced to the point where reading whole genomes is becoming routine. In 2003 the cost of sequencing an individual’s complete genome was in the order of millions of dollars, today it’s…

Continue Reading The data in our DNA | Opinion

European Commission Approves Tepkinly for Adults With Relapesed or Refractory Diffuse Large B-cell Lymphoma

The treatment is approved for conditional marketing authorization. AbbVie announced that Tepkinly has been approved for conditional marketing authorization by the European Commission. Tepkinly is a monotherapy for patients suffering from relapsed or refractory diffuse large B-cell lymphoma and have had at least two lines of systemic therapy. In a…

Continue Reading European Commission Approves Tepkinly for Adults With Relapesed or Refractory Diffuse Large B-cell Lymphoma

EC approval for AbbVie and Genmab lymphoma drug

The European Commission (EC) has granted conditional marketing authorization for Tepkinly (epcoritamab) as a monotherapy to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Tepkinly – from US drugmaker AbbVie (NYSE: ABBV) and Danish biotech Genmab (OMX: GEN) –…

Continue Reading EC approval for AbbVie and Genmab lymphoma drug

Lutathera Shows Promise as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors

On September 25, 2023, Novartis announced the release of groundbreaking findings from the Phase 3 NETTER-2 trial, which evaluated the efficacy of Lutathera as a radioligand therapy (RLT) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study successfully achieved its primary objective by demonstrating a significant improvement in progression-free survival (PFS)…

Continue Reading Lutathera Shows Promise as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors

Ambrx Biopharma (NYSE:AMAM) vs. CRISPR Therapeutics (NASDAQ:CRSP) Financial Survey

Ambrx Biopharma (NYSE:AMAM – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Analyst Recommendations This…

Continue Reading Ambrx Biopharma (NYSE:AMAM) vs. CRISPR Therapeutics (NASDAQ:CRSP) Financial Survey

AAD Reading Room | After Latest Findings, FDA Approval for Lebrikizumab Could Happen This Fall

Most patients with moderate-to-severe atopic dermatitis (AD) who received lebrikizumab (Adbry) every 2 weeks maintained a favorable response to the drug out to the 1-year mark, recent trial data showed. Perhaps just as importantly, people receiving the drug every 4 weeks maintained a substantial response, suggesting less-frequent treatments are required…

Continue Reading AAD Reading Room | After Latest Findings, FDA Approval for Lebrikizumab Could Happen This Fall

Diffuse Large B-cell Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

PRESS RELEASE Published September 21, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Diffuse Large B-cell Lymphoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Diffuse Large B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes…

Continue Reading Diffuse Large B-cell Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Mass spectrometry for expediting biologics to patients

A key element of development for new molecular format biological products is to leverage the appropriate analytical tools to enhance product and process understanding throughout the development lifecycle. Here, Ian Anderson, Mostafa Zarei and Qifeng Zhang at Lonza highlight the benefits of using mass spectrometry technologies to accelerate and de-risk product…

Continue Reading Mass spectrometry for expediting biologics to patients

Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX Cosmetic) for the Treatment of Platysma Prominence -September 19, 2023 at 05:30 am EDT

All primary and secondary endpoints were met for second Phase 3 study (M21-310) and results were consistent with findings from first Phase 3 study (M21-309). Results support onabotulinumtoxinA as a potential treatment option for moderate to severe platysma prominence. Data will be included as part of an upcoming U.S. Food…

Continue Reading Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX Cosmetic) for the Treatment of Platysma Prominence -September 19, 2023 at 05:30 am EDT

Diffuse Large B-cell Lymphoma Market to Show Immense Growth

New York, USA, Sept. 19, 2023 (GLOBE NEWSWIRE) — Diffuse Large B-cell Lymphoma Market to Show Immense Growth by 2032, Predicts DelveInsight | Leading Players to Look Out – AbbVie, Genmab, Merck, Xencor, Janssen, Roche, Biogen, Regeneron, Seagen, Takeda The DLBCL market has a diverse pipeline, with the emergence of…

Continue Reading Diffuse Large B-cell Lymphoma Market to Show Immense Growth

Five biotech companies taking Los Angeles by storm

Known throughout history for being home to the iconic scene of Hollywood, in recent years Los Angeles has also become a thriving biotech hub, after years of playing second fiddle in the U.S. to the likes of South San Francisco and Boston. In this article, we take a look at…

Continue Reading Five biotech companies taking Los Angeles by storm

Allergan Aesthetics: Second Phase 3 Study With OnabotulinumtoxinA Meets Endpoints

(RTTNews) – Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity. The company said all primary and secondary endpoints were met for second Phase…

Continue Reading Allergan Aesthetics: Second Phase 3 Study With OnabotulinumtoxinA Meets Endpoints

Positive Outcomes of Phase 3 Trial for BOTOX Cosmetic in Treating Platysma Prominence

Allergan Aesthetics has recently shared exciting news regarding the positive outcomes of their latest clinical trial, conducted as part of the Phase 3 studies for onabotulinumtoxinA (BOTOX® Cosmetic). The trial focused on assessing the effectiveness of this treatment in addressing the issue of moderate to severe platysma prominence, caused by…

Continue Reading Positive Outcomes of Phase 3 Trial for BOTOX Cosmetic in Treating Platysma Prominence

Scientist, Bioinformatics Engineer – South San Francisco

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

Continue Reading Scientist, Bioinformatics Engineer – South San Francisco

August 2023 Recap: Drug Pipeline Updates

Drug Pharmacologic Class Proposed Indication Status Allergic Disorders Remibrutinib (Novartis) Bruton tyrosine kinase inhibitor Treatment of chronic spontaneous urticaria in patients inadequately controlled by second generation H1 antihistamines. Phase 3 results Endocrine Disorders…

Continue Reading August 2023 Recap: Drug Pipeline Updates

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc,  (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection…

Continue Reading Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

DNA Sequencing Market worth $212.38 billion by 2030

DNA Sequencing Market | 360iResearch The “DNA Sequencing Market by Product & Services (Consumables, Instruments, Services), Technology (Next-Generation Sequencing, Sanger Sequencing, Third Generation DNA Sequencing), Workflow, Application – Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation – Global Forecast 2023-2030” report has been added to 360iResearch.com‘s offering. Request…

Continue Reading DNA Sequencing Market worth $212.38 billion by 2030

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

CAHtalyst™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline Daily Glucocorticoid Dose with Androgen Control Key Secondary Endpoint Achieved Statistically Significant Decrease in Androstenedione at Week 4 versus Placebo  Key Secondary Endpoint Demonstrated a Statistically Significant Number of Patients on Crinecerfont Achieved a…

Continue Reading Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

AbbVie to launch epcoritamab in the UAE

Dubai, United Arab Emirates: TEPKINLY™ (epcoritamab) has received conditional regulatory approval in the United Arab Emirates (UAE) on August 15th 2023, being the first country after the country of origin (United States) to grant conditional regulatory approval. This milestone marks a significant step forward in the field of oncology and offers…

Continue Reading AbbVie to launch epcoritamab in the UAE

High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody

HOUSTON — More than 60% of patients with relapsed/refractory large B-cell lymphoma (LBCL) had objective responses to the bispecific antibody epcoritamab (Epkinly), according to updated results from a pivotal trial. Overall, 63% of 157 patients responded, including 39% who had complete responses. Responses by lymphoma subtype consisted of 61% of…

Continue Reading High Rate of Durable Responses in R/R Lymphoma With Bispecific Antibody

The New Algorithm for Second-Line Large B-Cell Lymphoma Treatment

New enhanced treatment options with prolonged overall survival are improving patient outcomes in diffuse large B-cell lymphoma (DLBCL), according to Jason Westin, MD, director of Lymphoma Clinical Research Program and section chief of Aggressive Lymphoma, Department of Lymphoma and Melanoma at The University of Texas MD Anderson Cancer Center in…

Continue Reading The New Algorithm for Second-Line Large B-Cell Lymphoma Treatment

DelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MM

PRESS RELEASE Published September 9, 2023 The B-Cell Lymphoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of B-Cell Lymphoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the B-Cell Lymphoma…

Continue Reading DelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MM

What DLBCL Clinical Trials are Available to Me?

September 7, 2023 What Clinical Trials are Available to Me? Edited by:Katrina Villareal Experts and patients discuss the latest in diffuse large B-cell lymphoma (DLBCL). Dr. Josh Brody of Mount Sinai Hospital, clinical trial nurse navigator Crissy Kus of The Leukemia & Lymphoma Society, and DLBCL survivor Dr. Robyn Stacy-Humphries…

Continue Reading What DLBCL Clinical Trials are Available to Me?

Imminent Phase 3 Trials To Treat PTSD And SAD Send Bionomics Ltd. Stock Higher By Over 60% Since August ($BNOX)

PRESS RELEASE Published September 8, 2023 Bionomics Limited (Nasdaq: BNOX) (ASX: BNO) shares are attracting investor attention. And rightly so, noting that the company is nearing the commencement of potentially two near-term Phase 3 trials to treat critical unmet medical needs. The first to enter the Phase 3 arena could…

Continue Reading Imminent Phase 3 Trials To Treat PTSD And SAD Send Bionomics Ltd. Stock Higher By Over 60% Since August ($BNOX)

Janssen Pharmaceutical Companies Halts Phase 3 MACiTEPH Study on Macitentan in CTEPH Patients

On September 6, 2023, Janssen Pharmaceutical Companies of Johnson & Johnson made a significant announcement regarding their Phase 3 MACiTEPH study. The study was focused on evaluating the effectiveness of macitentan 75 mg in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). However, due to futility, Janssen Pharmaceutical Companies have decided…

Continue Reading Janssen Pharmaceutical Companies Halts Phase 3 MACiTEPH Study on Macitentan in CTEPH Patients

Phase 3 MARIPOSA2 Study A Breakthrough in Treating EGFRMutated NSCLC

Introducing the groundbreaking Phase 3 MARIPOSA-2 study, conducted on September 6, 2023. This clinical trial aimed to delve into the effectiveness of RYBREVANT® (amivantamab-vmjw) in combination with chemotherapy, both with and without lazertinib, as opposed to chemotherapy alone. The focus was on patients suffering from EGFR-mutated non-small cell lung cancer…

Continue Reading Phase 3 MARIPOSA2 Study A Breakthrough in Treating EGFRMutated NSCLC

Efficient gene knockout and genetic interactions: the IN4MER CRISPR/Cas12a multiplex knockout platform

Abstract Genetic interactions mediate the emergence of phenotype from genotype, but initial technologies for combinatorial genetic perturbation in mammalian cells suffer from inefficiency and are challenging to scale. Recent focus on paralog synthetic lethality in cancer cells offers an opportunity to evaluate different approaches and improve on the state of…

Continue Reading Efficient gene knockout and genetic interactions: the IN4MER CRISPR/Cas12a multiplex knockout platform

Propulsion of Amyotrophic Lateral Sclerosis Clinical Trial Pipeline as Novel and Extensive 100+ Therapies Likely to Enter in the Domain

PRESS RELEASE Published August 29, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the Amyotrophic Lateral Sclerosis Pipeline constitutes 90+ key companies continuously working towards developing 100+ Amyotrophic Lateral Sclerosis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.  …

Continue Reading Propulsion of Amyotrophic Lateral Sclerosis Clinical Trial Pipeline as Novel and Extensive 100+ Therapies Likely to Enter in the Domain

ASCO Reading Room | Manali Kamdar, MD, on Practical Considerations for Using CAR T-Cells for DLBCL

The advent of chimeric antigen receptor (CAR) T-cell therapy has dramatically changed the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Upfront chemoimmunotherapy cures most patients with DLBCL, but approximately 30-40% will relapse. Although in some cases autologous stem-cell transplantation (ASCT) offers a second chance at a durable remission, patients…

Continue Reading ASCO Reading Room | Manali Kamdar, MD, on Practical Considerations for Using CAR T-Cells for DLBCL

Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain

PRESS RELEASE Published August 28, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the PD-1 Non-Small Cell Lung Cancer Pipeline constitutes 30+ key companies continuously working towards developing 30+ PD-1 Non-Small Cell Lung Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and…

Continue Reading Propulsion of PD-1 Non-Small Cell Lung Cancer Clinical Trial Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Domain

Risankizumab Under Review for Moderately to Severely Active Ulcerative Colitis

AbbVie has submitted a regulatory application to the Food and Drug Administration (FDA) seeking approval of risankizumab for the treatment of adults with moderately to severely active ulcerative colitis. The application is supported by data from two phase 3 trials: an induction study, INSPIRE (ClinicalTrials.gov Identifier: NCT03398148) and a maintenance…

Continue Reading Risankizumab Under Review for Moderately to Severely Active Ulcerative Colitis

The global bone cancer treatment market size was valued at USD 2.1 billion in 2023 and is projected to reach USD 2.9 billion by 2030, exhibiting a CAGR of 5.2% from 2023 to 2030.

PRESS RELEASE Published August 25, 2023 List of reports available with us. Bone Cancer Treatment Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Cervical Cancer Market Size / CAGR / Sales Revenue   (Request Free Sample Report) Cervical Cancer Vaccine Market Size / CAGR / Sales Revenue   (Request…

Continue Reading The global bone cancer treatment market size was valued at USD 2.1 billion in 2023 and is projected to reach USD 2.9 billion by 2030, exhibiting a CAGR of 5.2% from 2023 to 2030.

BioSpace hiring Principal Research Scientist II, Bioinformatics in South San Francisco, California, United States

Since 2013, AbbVie has expanded its commitment to the San Francisco Bay Area with the consolidation of three Bay Area facilities to a new Bay Area headquarters in South San Francisco. AbbVie employees in the Bay Area drive AbbVie’s research-based, innovation driven missions in healthcare. Specifically, Bay Area employees bring…

Continue Reading BioSpace hiring Principal Research Scientist II, Bioinformatics in South San Francisco, California, United States

Principal Research Scientist II, Bioinformatics – South San Francisco

Since 2013, AbbVie has expanded its commitment to the San Francisco Bay Area with the consolidation of three Bay Area facilities to a new Bay Area headquarters in South San Francisco. AbbVie employees in the Bay Area drive AbbVie’s research-based, innovation driven missions in healthcare. Specifically, Bay Area employees bring…

Continue Reading Principal Research Scientist II, Bioinformatics – South San Francisco

Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Analysis

Las Vega (Nevada), United States //- As per DelveInsight’s assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Diffuse Large B-cell Lymphoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies…

Continue Reading Diffuse Large B-cell Lymphoma (DLBCL) Pipeline Analysis

Epcoritamab plus R-CHOP achieve high response rates in untreated high-risk DLBCL

August 21, 2023 1 min read Source/Disclosures Published by: Source: Falchi L, et al. Abstract 7519. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Falchi reports consulting and funding from AbbVie, ADC Therapeutics, AstraZeneca, Genmab, Roche/Genentech and Seagen. ADD TOPIC TO EMAIL ALERTS Receive an email when new…

Continue Reading Epcoritamab plus R-CHOP achieve high response rates in untreated high-risk DLBCL

Epcoritamab: First Approval – PubMed

Review doi: 10.1007/s40265-023-01930-4. Online ahead of print. Affiliations Expand Affiliation 1 Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com. Item in Clipboard Review James E Frampton. Drugs. 2023. Show details Display options Display options Format AbstractPubMedPMID doi: 10.1007/s40265-023-01930-4. Online ahead of print. Affiliation 1 Springer Nature,…

Continue Reading Epcoritamab: First Approval – PubMed

Epcoritamab: First Approval | SpringerLink

AbbVie. EPKINLY™ (epcoritamab-bysp) approved by U.S. FDA as the first and only bispecific antibody to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [media release]. 19 May 2023. www.abbvie.com. Genmab US, Inc. EPKINLY™ (epcoritamab-bysp) injection, for subcutaneous use: US prescribing information. 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324Orig1s000lbl.pdf. Accessed 21 June…

Continue Reading Epcoritamab: First Approval | SpringerLink

AbbVie, Amgen, AstraZeneca, Bayer, and Merck

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced the five founding members of the Alliance for Genomic Discovery (AGD). The…

Continue Reading AbbVie, Amgen, AstraZeneca, Bayer, and Merck

Diffuse Large B-cell Lymphoma Therapeutics Market 2023-2032:

Diffuse Large B-cell Lymphoma Therapeutics Market The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies increasing incidence of diffuse large B-cell…

Continue Reading Diffuse Large B-cell Lymphoma Therapeutics Market 2023-2032:

Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript

Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript August 10, 2023 Operator: Good day, ladies and gentlemen, and welcome to the Second Quarter 2023 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be…

Continue Reading Illumina, Inc. (NASDAQ:ILMN) Q2 2023 Earnings Call Transcript

Senior Scientist, Bioinformatics I job in North Chicago at AbbVie

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist I/II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

Continue Reading Senior Scientist, Bioinformatics I job in North Chicago at AbbVie

SpA-Related Diseases Share Gut Microbiota Dysbiosis

TOPLINE: Patients with spondyloarthritis (SpA) experience similar gut microbiota dysbiosis with related inflammatory conditions, such as acute anterior uveitis (AAU) and Crohn’s disease (CD), new data show. METHODOLOGY: Researchers performed 16S rRNA sequencing on stool samples from 277 adult patients from the German Spondyloarthritis Inception Cohort (102 with SpA, 72…

Continue Reading SpA-Related Diseases Share Gut Microbiota Dysbiosis

AbbVie hiring Sr. Scientist I, Bioinformatics in Irvine, California, United States

The Toxin Innovation Group at AbbVie seeks a highly skilled and motivated bioinformatics scientist (Senior Scientist I, bioinformatics) focused on novel neurotoxin discovery research. The Senior Scientist will play an integral role in our research team, contributing to the generation, analysis and interpretation of genomic data to advance our understanding…

Continue Reading AbbVie hiring Sr. Scientist I, Bioinformatics in Irvine, California, United States

Bioinformatics Platforms Market 2023-2028 Global Key Manufacturers

PRESS RELEASE Published August 9, 2023 The Bioinformatics Platforms Market report outlines the evolution of Bioinformatics Platforms Market by type, applications and identifies and assesses the best performing vendors in the market till 2028. Bioinformatics Platforms Market reports present the revenue opportunities in the Bioinformatics Platforms Industry through 2023-2028, highlighting the market…

Continue Reading Bioinformatics Platforms Market 2023-2028 Global Key Manufacturers

CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

CytomX Therapeutics Inc. – CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 – – IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 – – Management to hold conference call today at 5 p.m. EDT / 2…

Continue Reading CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Microbiome Study Provides New Clues to Common Pathology of Inflammatory Conditions

An alteration in gut microbiome diversity occurred in patients with three different inflammatory conditions, suggesting a common pathology, prospective rRNA sequencing of patients’ stool samples showed. Patients with axial spondyloarthritis (SpA), acute anterior uveitis (AAU), and Crohn’s disease had a low concentration of Lachnospiraceae compared with a control group of…

Continue Reading Microbiome Study Provides New Clues to Common Pathology of Inflammatory Conditions

CytomX Therapeutics Reports Second Quarter 2023 Financial

– CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 –                         – IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) anticipated in the fourth quarter of 2023 – – Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT –…

Continue Reading CytomX Therapeutics Reports Second Quarter 2023 Financial

Genmab Announces Financial Results for the First Half of 2023

Genmab A/S August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Genmab…

Continue Reading Genmab Announces Financial Results for the First Half of 2023

Aug. 3, 2023, San Diego Metro Magazine

Can field sobriety tests identify drivers under the influence of cannabis? By Nicole Mlynaryk | UC San Diego Road safety is a critical issue in an era of increasing cannabis legalization. Cannabis is known to impair reaction time, decision-making, coordination and perception—skills necessary for safe driving. In the last three…

Continue Reading Aug. 3, 2023, San Diego Metro Magazine

Genmab Announces Financial Results for the First Half of

August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Genmab and AbbVie…

Continue Reading Genmab Announces Financial Results for the First Half of

Humira Biosimilar Market to surpass $3,871.4 Million by

Burlingame, July 28, 2023 (GLOBE NEWSWIRE) — The global Humira biosimilar Market is approximated to be $772.1 million in 2023, and it is projected to reach $3,871.4 million by 2030 at a CAGR of 25.9%., as per the recent study by Coherent Market Insights, Inc. Haldima, a latest biosimilar of…

Continue Reading Humira Biosimilar Market to surpass $3,871.4 Million by

Illumina Announces New Genomics Alliance, Software for Analyzing Genomic Data, Understanding Disease Molecules, More

July 27, 2023 | Illumina announces the five founding members of the Alliance of Genomic Discovery and launches the newest version of DRAGEN software, the Allen Institute for Immunology and Eli Lilly team up to better understand disease molecules, and crowd-sourced neuroscience. Plus, product updates, partnerships, and acquisitions from Sinequa,…

Continue Reading Illumina Announces New Genomics Alliance, Software for Analyzing Genomic Data, Understanding Disease Molecules, More

First patient dosed in global phase 3 trial of Rinvoq for hidradenitis suppurativa

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later….

Continue Reading First patient dosed in global phase 3 trial of Rinvoq for hidradenitis suppurativa

AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

AbbVie has announced that the first patient has been dosed in a late-stage study of its selective JAK inhibitor, Rinvoq (upadacitinib), in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS). HS is a long-term skin condition that causes painful bumps, nodules or abscesses that can leak fluid and lead to…

Continue Reading AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa

R/R DLBCL Treatment Receives FDA Approval | ASH Clinical News

The U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified in adults. The indication also includes DLBCL that arises from indolent lymphoma and high-grade B-cell lymphoma after at least two prior lines of therapy. Approval…

Continue Reading R/R DLBCL Treatment Receives FDA Approval | ASH Clinical News

AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ) in Hidradenitis Suppurativa

NORTH CHICAGO – AbbVie (NYSE: ABBV) today announced that the first patient has been dosed in the Phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy…

Continue Reading AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ) in Hidradenitis Suppurativa

AbbVie’s Epcoritamab Gets CHMP Nod for DLBCL

Source – AbbVieAbbVie and Genmab’s potential blockbuster drug epcoritamab has received a favorable recommendation for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of non-Hodgkin’s lymphoma. The European Medicines Agency’s human medicines committee (CHMP) has issued a positive opinion on…

Continue Reading AbbVie’s Epcoritamab Gets CHMP Nod for DLBCL

AbbVie (ABBV) has ‘near-term headwinds but stable longer-term growth’

William Blair analyst Lachlan Hanbury-Brown initiated coverage of AbbVie (NYSE: ABBV) with a Market Perform rating in a note to clients Tuesday. The analyst told investors that the company’s Humira LOE, Imbruvica competition, and aesthetics risks overshadow its new products. “We believe we are roughly six months into the mother…

Continue Reading AbbVie (ABBV) has ‘near-term headwinds but stable longer-term growth’

Principal Research Scientist II, Bioinformatics Job Opening in South San Francisco, CA at AbbVie

Since 2013, AbbVie has expanded its commitment to the San Francisco Bay Area with the consolidation of three Bay Area facilities to a new Bay Area headquarters in South San Francisco. AbbVie employees in the Bay Area drive AbbVie’s research-based, innovation driven missions in healthcare. Specifically, Bay Area employees bring…

Continue Reading Principal Research Scientist II, Bioinformatics Job Opening in South San Francisco, CA at AbbVie

First Patient Receives Upadacitinib in Phase 3 Trial For Treatment of Hidradenitis Suppurativa

AbbVie announced that the first patient has received treatment in its phase 3 Step-Up HS study.1 The study is assessing the effectiveness of upadacitinib (Rinvoq) in treating moderate to severe hidradenitis suppurativa (HS) in adults and adolescents in whom anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy…

Continue Reading First Patient Receives Upadacitinib in Phase 3 Trial For Treatment of Hidradenitis Suppurativa

Epcoritamab gains positive opinion for lymphoma therapy

AbbVie’s epcoritamab is intended to treat adult patients with relapsed/refractory DLBCL. Credit: AbbVie Inc. AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for epcoritamab (TEPKINLY) to treat adults with relapsed or refractory (R/R) diffuse large B-cell…

Continue Reading Epcoritamab gains positive opinion for lymphoma therapy

2023-07-24 | NYSE:ABBV | Press Release

– First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ®) in adults and adolescents with moderate to severe HS1 – HS is a difficult-to-treat chronic, inflammatory disease with few therapeutic options available2,3 – AbbVie applies proven expertise in immunology and HS…

Continue Reading 2023-07-24 | NYSE:ABBV | Press Release

Bispecific Antibody Market revenue to cross USD 1 Billion

New York, July 24, 2023 (GLOBE NEWSWIRE) — The global bispecific antibody market size is slated to expand at ~7% CAGR between 2023 and 2035. The market is poised to garner a revenue of USD 1 billion by the end of 2035, up from a revenue of ~USD 500 million…

Continue Reading Bispecific Antibody Market revenue to cross USD 1 Billion

Diffuse Large B-cell Lymphoma (DLBCL) Market Report 2032:

Diffuse Large B-cell Lymphoma (DLBCL) Market (New York, USA) DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Diffuse Large B-cell Lymphoma (DLBCL), historical and forecasted epidemiology as well as the Diffuse Large B-cell Lymphoma (DLBCL) market trends in the United…

Continue Reading Diffuse Large B-cell Lymphoma (DLBCL) Market Report 2032:

Epcoritamab and talquetamab near EMA approval in cancer

Epcoritamab Image courtesy of Genmab The European Medicines Agency (EMA) could soon change the face of cancer treatment with its potential approval of two novel bispecific antibodies, epcoritamab and talquetamab. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting conditional marketing authorization for two novel cancer…

Continue Reading Epcoritamab and talquetamab near EMA approval in cancer

Life Science Tennessee and BioTN Foundation Congratulate Nashville Biosciences’ Formation of the Alliance for Genomic Discovery

Nashville Biosciences, VUMC’s extensive genomic and bioinformatics database subsidiary, has partnered with five of the world’s leading pharma companies to create the largest de-identified WGS database in the world NASHVILLE, Tenn.–(BUSINESS WIRE)–Nashville Biosciences (NB), a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), has announced a partnership with five…

Continue Reading Life Science Tennessee and BioTN Foundation Congratulate Nashville Biosciences’ Formation of the Alliance for Genomic Discovery

VUMC subsidiary partnering with more pharma companies on sequencing | Health Care

Nashville Biosciences, a for-profit subsidiary of Vanderbilt University Medical Center, is expanding its genomic sequencing efforts by partnering with more major pharmaceutical companies. The entity is forming the Alliance for Genomic Discovery with Abbvie, Amgen, AstraZeneca, Bayer and Merck, according to a release. The effort is also supported by Illumina,…

Continue Reading VUMC subsidiary partnering with more pharma companies on sequencing | Health Care

Epcoritamab Approaches EU Approval for Relapsed/Refractory DLBCL

Image Credit: ©Dr_Microbe – stock.adobe.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending conditional marketing authorization to epcoritamab-bysp (Tepkinly) monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after 2 or more lines of…

Continue Reading Epcoritamab Approaches EU Approval for Relapsed/Refractory DLBCL

Summary of opinion: Tepkinly,epcoritamab, 20/07/2023, Positive

On 20 July 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional1 marketing authorisation for the medicinal product Tepkinly2, intended for the treatment of diffuse large B‑cell lymphoma (DLBCL). The applicant for this medicinal product is AbbVie Deutschland GmbH &…

Continue Reading Summary of opinion: Tepkinly,epcoritamab, 20/07/2023, Positive

Alliance for Genomic Discovery announces its five founding biopharma members

The five founding members of the Alliance for Genomic Discovery (AGD), a project aiming to accelerate therapeutic development and expand the diversity of genomic data, have been announced. Joining the AGD are AstraZeneca, AbbVie, Amgen, Bayer and Merck, who will co-fund the whole-genome sequencing of 250,000 samples in a biobank…

Continue Reading Alliance for Genomic Discovery announces its five founding biopharma members

ctDNA negative status contributes to positive outcomes for DLBCL

Source/Disclosures Published by: Source: Herrera, A, et al. Abstract 7523. Presented at: American Society of Clinical Oncology Meeting; June 2-6, 2023; Chicago. Disclosures: Herrera reports consulting and funding from Abbvie, ADC Therapeutics, Adicet Bio, AstraZeneca/MedImmune, Bristol-Myers Squibb, Caribou Biosciences, Genentech/Roche, Genmab, Gilead Sciences, Karyopharm Therapeutics, Kite, a…

Continue Reading ctDNA negative status contributes to positive outcomes for DLBCL

Seven pharma companies form alliance to prepare for pandemics

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics.  The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The alliance creation is in support of the 100 Days Mission,…

Continue Reading Seven pharma companies form alliance to prepare for pandemics

Treatment of adults with relapsed or refractory DLBCL

Introduction Diffuse Large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), accounting for 31% of NHL cases in Western countries.1,2 The median age at presentation is 66, and 5-year survival rates decrease by age from 78% for those younger than 55 years to 54% for those over 65…

Continue Reading Treatment of adults with relapsed or refractory DLBCL

Alliance for Genomic Discovery Announces Five Founding Biopharma Members

The first cohort of major biopharma members to the Alliance for Genomic Discovery (AGD) has been announced. The five founding members are AbbVie, Amgen, AstraZeneca, Bayer, and Merck. Launched in 2022 by Illumina and Nashville Biosciences, the Alliance for Genomic Discovery is a multiyear endeavor aiming to accelerate the development…

Continue Reading Alliance for Genomic Discovery Announces Five Founding Biopharma Members

Members of the Alliance for Genomic Discovery revealed

Illumina and Nashville Biosciences’ have announced AbbVie, Amgen, AstraZeneca, Bayer and Merck as founding members Illumina – a company focused on in DNA sequencing – in collaboration with Nashville Biosciences, a genomic data company, have revealed the founding members of the ‘Alliance for Genomic Discovery’ (AGD). Nashville…

Continue Reading Members of the Alliance for Genomic Discovery revealed

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck – Illumina (NASDAQ:ILMN)

Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries SAN DIEGO, July 18, 2023 /PRNewswire/ — Illumina Inc. ILMN, a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and…

Continue Reading The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck – Illumina (NASDAQ:ILMN)

Bioconductor – SCArray.sat

DOI: 10.18129/B9.bioc.SCArray.sat   Large-scale single-cell RNA-seq data analysis using GDS files and Seurat Bioconductor version: Release (3.17) Extends the Seurat classes and functions to support Genomic Data Structure (GDS) files as a DelayedArray backend for data representation. It relies on the implementation of GDS-based DelayedMatrix in the SCArray package to…

Continue Reading Bioconductor – SCArray.sat

Alliance for Genomic Discovery FAQs | VUMC Reporter

Alliance for Genomic Discovery (AGD) FAQs – July 2023 – What is Nashville Biosciences? Nashville Biosciences (“NashBio”) is a wholly owned for-profit subsidiary of VUMC, launched in 2018 (www.nashville.bio/).   Read the news: The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer and Merck Why was…

Continue Reading Alliance for Genomic Discovery FAQs | VUMC Reporter

Discussing The Role of Acalabrutinib in Triplet Therapy for MCL

The addition of the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (Calquence) to the combination of bendamustine (Bendeka) and rituximab (Rituxan) proved to be tolerable and effective enough to warrant expansion to a phase 3 trial for patients with either treatment-naive or relapsed/refractory mantle cell lymphoma (MCL).1 These data were presented…

Continue Reading Discussing The Role of Acalabrutinib in Triplet Therapy for MCL

Caribou Biosciences: Well Positioned To Trailblaze

Curing cancer is not easy. It’s a long, expensive road for even the most bold scientists and investors. In today’s tight funding environment, many biotechs will never get a chance to bring their science to fruition. But Caribou Biosciences ($CRBU) stands out from the pack. A recent investment by a…

Continue Reading Caribou Biosciences: Well Positioned To Trailblaze

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with Halozyme’s ENHANZE Drug Delivery Technology in Patients with Multiple Sclerosis

SAN DIEGO – Halozyme Therapeutics, Inc. (NASDAQ: HALO) (‘Halozyme‘) today announced that Roche’s Phase 3 OCARINA II trial evaluating OCREVUS with ENHANZE as a twice a year 10-minute subcutaneous (SC) injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS…

Continue Reading Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with Halozyme’s ENHANZE Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics (HALO) Reports Positive Data from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with ENHANZE

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme“) today announced that Roche’s Phase 3 OCARINA II trial evaluating OCREVUS® (ocrelizumab) with ENHANZE® as a twice a year 10-minute subcutaneous (SC) injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis (MS) or primary progressive MS (RMS or…

Continue Reading Halozyme Therapeutics (HALO) Reports Positive Data from Phase 3 OCARINA II Trial Evaluating Roche’s OCREVUS with ENHANZE

Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval

Roche RHHBY obtained conditional marketing authorization from the European Commission (EC) for its lymphoma drug Columvi (glofitamab). The drug has been approved for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The approval is based…

Continue Reading Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval

EC Approves Roche’s Bispecific Antibody Columvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Credit: CoRus13 via Wikimedia Commons Roche announced today that the European Commission (EC) has granted conditional marketing approval for its bispecific antibody (bsAb) glofitamab, sold under the trade name Columvi, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines…

Continue Reading EC Approves Roche’s Bispecific Antibody Columvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Systemic Lupus Erythematosus Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 55+ Companies are working to improve the Treatment of Space

PRESS RELEASE Published July 11, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the Systemic Lupus Erythematosus pipeline constitutes 55+ key companies continuously working towards developing 60+ Systemic Lupus Erythematosus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.   In…

Continue Reading Systemic Lupus Erythematosus Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 55+ Companies are working to improve the Treatment of Space

European Commission approves Roche’s fixed-duration Columvi

Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available in Europe to treat the most common and aggressive form of lymphoma Approval is based on results from the phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated…

Continue Reading European Commission approves Roche’s fixed-duration Columvi

Cassava Science positive data continues to derisk ongoing phase 3 trials (NASDAQ:SAVA)

adamkaz/E+ via Getty Images I once again give Cassava Sciences (NASDAQ:SAVA) a strong buy rating, and as I have previously stated, I think Cassava Sciences is the best risk to reward on the market. I have been covering this stock for three years and have been very bullish on it…

Continue Reading Cassava Science positive data continues to derisk ongoing phase 3 trials (NASDAQ:SAVA)

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

Selection and sequencing of CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer hinge on the maturation of data in the first-line setting and beyond, and these decisions need to account for patient concerns and preferences, according to Sarah Sammons, MD. Primary results from the phase 3…

Continue Reading CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

Presbyopia Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 12+ Companies are working to improve the Treatment of Space

PRESS RELEASE Published July 6, 2023 (Albany, United States) As per DelveInsight’s assessment, globally, the Presbyopia pipeline constitutes 12+ key companies continuously working towards developing 12+ Presbyopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.   In the Presbyopia Pipeline Report,…

Continue Reading Presbyopia Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 12+ Companies are working to improve the Treatment of Space

Epcoritamab Produces Positive Responses in R/R Follicular Lymphoma

The FDA approved epcoritamab for treating relapsed/refractory DLBCL and high-grade B-cell lymphoma in May 2023. The investigational bispecific antibody epcoritamab-bysp (Epkinly) yielded responses exceeding the protocol prespecified threshold for efficacy among pretreated patients with relapsed/refractory follicular lymphoma, according to a press release on topline results from the phase 1/2 EPCORE…

Continue Reading Epcoritamab Produces Positive Responses in R/R Follicular Lymphoma

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors. The Board has elected three new independent board members…

Continue Reading NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

10 Promising Biotech Stocks In The Medical Field

The Birthplace Of Medical Revolution While biotechnology is a very large field, its largest impact is in the medical field. Medicine has for a long time mostly guessed at what was wrong in the body of patients. Even when it became more scientifically driven, it still had to rely on…

Continue Reading 10 Promising Biotech Stocks In The Medical Field

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

Results from the phase 1/2 EPCORE-NHL-1 clinical trial show that epcoritamab produced an 82% overall response rate (ORR) for patients with relapsed/refractory (R/R) follicular lymphoma (FL), who make up one cohort of patients in the study evaluating the T-cell engaging bispecific antibody. Topline results for the FL cohort of the…

Continue Reading Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies

Abstract Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual data from 13 clinical studies of…

Continue Reading Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies

NCCN Adds Epcoritamab to Clinical Practice Guidelines for B-Cell Lymphomas

Epcoritamab (Epkinly) has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for patients with B-cell lymphomas.1 This addition is for the treatment of patients as third line and subsequent therapy for patients with diffuse large B-cell lymphoma (DLBCL) with disease progression after…

Continue Reading NCCN Adds Epcoritamab to Clinical Practice Guidelines for B-Cell Lymphomas

AbbVie takes step forward in Europe with migraine drug

AbbVie says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month.  If approved, AbbVie will be the only company to…

Continue Reading AbbVie takes step forward in Europe with migraine drug

Recent FDA Actions: June 2023

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.1 The regulatory decision was supported by data from the…

Continue Reading Recent FDA Actions: June 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Newly released data from the ongoing phase I/II EPCORE NHL-2 trial show the T-cell-engaging bispecific antibody epcoritamab (Epkinly) led to a high overall response rate and complete metabolic response rate when used in combination with rituximab (Rituxan) and lenalidomide (Revlimid) in patients with relapsed or refractory follicular lymphoma (R/R FL).1…

Continue Reading New Epcoritamab Data Show Strong Results in B-Cell Lymphomas